S-Homocysteinylation effects on transthyretin: Worsening of cardiomyopathy onset.

[1]  S. Doglia,et al.  A FTIR microspectroscopy study of the structural and biochemical perturbations induced by natively folded and aggregated transthyretin in HL-1 cardiomyocytes , 2018, Scientific Reports.

[2]  D. Nagaraja,et al.  Relevance of plasma levels of free homocysteine and methionine as risk predictors for ischemic stroke in the young. , 2017, Clinical nutrition.

[3]  M. Bucciantini,et al.  Biochemical and Electrophysiological Modification of Amyloid Transthyretin on Cardiomyocytes. , 2016, Biophysical journal.

[4]  C. Dobson,et al.  Effect of molecular chaperones on aberrant protein oligomers in vitro: super-versus sub-stoichiometric chaperone concentrations , 2016, Biological chemistry.

[5]  Qin Yang,et al.  Inhibitory effect of human serum albumin on Cu-induced Aβ(40) aggregation and toxicity. , 2015, European journal of pharmacology.

[6]  D. Del Rio,et al.  Transthyretin Binding Heterogeneity and Anti-amyloidogenic Activity of Natural Polyphenols and Their Metabolites* , 2015, The Journal of Biological Chemistry.

[7]  L. Fassina,et al.  Arsenic trioxide alters the differentiation of mouse embryonic stem cell into cardiomyocytes , 2015, Scientific Reports.

[8]  M. Ikram,et al.  Cardiovascular risk factors and future risk of Alzheimer’s disease , 2014, BMC Medicine.

[9]  C. Robinson,et al.  Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis , 2014, Proceedings of the National Academy of Sciences.

[10]  P. Wright,et al.  Mechanisms of Transthyretin Inhibition of β-Amyloid Aggregation In Vitro , 2013, The Journal of Neuroscience.

[11]  F. Chiti,et al.  Transthyretin suppresses the toxicity of oligomers formed by misfolded proteins in vitro. , 2013, Biochimica et biophysica acta.

[12]  R. Bellazzi,et al.  Mouse embryonic stem cells irradiated with γ-rays differentiate into cardiomyocytes but with altered contractile properties. , 2013, Mutation research.

[13]  J. Buxbaum,et al.  Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. , 2013, Biochemistry.

[14]  S. Sengupta,et al.  S-linked protein homocysteinylation: identifying targets based on structural, physicochemical and protein–protein interactions of homocysteinylated proteins , 2013, Amino Acids.

[15]  M. Saraiva,et al.  Distinct Annular Oligomers Captured along the Assembly and Disassembly Pathways of Transthyretin Amyloid Protofibrils , 2012, PloS one.

[16]  L. Deiana,et al.  LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[17]  A. Planas,et al.  Methods to evaluate the inhibition of TTR fibrillogenesis induced by small ligands. , 2012, Current medicinal chemistry.

[18]  G. Mazzini,et al.  Mouse embryonic stem cells that survive γ‐rays exposure maintain pluripotent differentiation potential and genome stability , 2012, Journal of cellular physiology.

[19]  A. Cimmino,et al.  Homocysteinylated Albumin Promotes Increased Monocyte-Endothelial Cell Adhesion and Up-Regulation of MCP1, Hsp60 and ADAM17 , 2012, PloS one.

[20]  Giovanni Magenes,et al.  Video Evaluation of the Kinematics and Dynamics of the Beating Cardiac Syncytium: An Alternative to the Langendorff Method , 2011, The International journal of artificial organs.

[21]  F. Salvi,et al.  Systemic Cardiac Amyloidoses: Disease Profiles and Clinical Courses of the 3 Main Types , 2009, Circulation.

[22]  Toshio Shimizu,et al.  Characterization of cysteine and homocysteine bound to human serum transthyretin. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[23]  M. V. van Oijen,et al.  Prognostic value of free plasma homocysteine levels in patients hospitalized with acute coronary syndrome. , 2008, The American journal of cardiology.

[24]  D. Giustarini,et al.  Cysteinylation and homocysteinylation of plasma protein thiols during ageing of healthy human beings , 2008, Journal of cellular and molecular medicine.

[25]  F. Chiti,et al.  Conformational properties of the aggregation precursor state of HypF-N. , 2008, Journal of Molecular Biology.

[26]  T. Laue,et al.  The Modulation of Transthyretin Tetramer Stability by Cysteine 10 Adducts and the Drug Diflunisal , 2008, Journal of Biological Chemistry.

[27]  Pritam Das,et al.  Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Aβ toxicity , 2008, Proceedings of the National Academy of Sciences.

[28]  D. Jacobsen,et al.  Molecular targeting of proteins by L-homocysteine: mechanistic implications for vascular disease. , 2007, Antioxidants & redox signaling.

[29]  D. Jacobsen,et al.  Targeting of Metallothionein by L-Homocysteine: A Novel Mechanism for Disruption of Zinc and Redox Homeostasis , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[30]  S. Vollset,et al.  The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. , 2006, The Journal of nutrition.

[31]  D. Jacobsen,et al.  Molecular targeting by homocysteine: a mechanism for vascular pathogenesis , 2005, Clinical chemistry and laboratory medicine.

[32]  Masaaki Nakamura,et al.  Transthyretin-related familial amyloidotic polyneuropathy. , 2005, Archives of neurology.

[33]  W. Claycomb,et al.  Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. , 2004, American journal of physiology. Heart and circulatory physiology.

[34]  S. Sengupta,et al.  In Vitro and in Vivo Interactions of Homocysteine with Human Plasma Transthyretin* , 2003, Journal of Biological Chemistry.

[35]  J. Sass,et al.  S-homocysteinylation of transthyretin is detected in plasma and serum of humans with different types of hyperhomocysteinemia. , 2003, Biochemical and biophysical research communications.

[36]  J. Kelly,et al.  Cys10 mixed disulfides make transthyretin more amyloidogenic under mildly acidic conditions. , 2003, Biochemistry.

[37]  F. Real,et al.  New Insights into the tPA-Annexin A2 Interaction , 2003, The Journal of Biological Chemistry.

[38]  David Tweedie,et al.  Differentiation of Pluripotent Embryonic Stem Cells Into Cardiomyocytes , 2002, Circulation research.

[39]  S. Sengupta,et al.  Homocysteine Binds to Human Plasma Fibronectin and Inhibits Its Interaction With Fibrin , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[40]  J. Kelly,et al.  Support for the multigenic hypothesis of amyloidosis: The binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[41]  T. Orfeo,et al.  Homocysteine Inhibits Inactivation of Factor Va by Activated Protein C* , 2001, The Journal of Biological Chemistry.

[42]  W. Hornebeck,et al.  Influence of homocysteine on matrix metalloproteinase-2: activation and activity. , 1999, Biochemical and biophysical research communications.

[43]  J. Kelly,et al.  Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation. , 1998, Biochemistry.

[44]  R. Brito,et al.  The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution , 1997, FEBS letters.

[45]  W. Strittmatter,et al.  Transthyretin sequesters amyloid beta protein and prevents amyloid formation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[46]  P. Ueland,et al.  Redox status and protein binding of plasma homocysteine and other aminothiols in patients with homocystinuria. , 1993, Metabolism: clinical and experimental.

[47]  D. Feinstein,et al.  Pathomolecular effects of homocysteine on the aging process: a new theory of aging. , 2007, Medical hypotheses.